Last updated: June 9, 2025
Sponsor: Zagazig University
Overall Status: Active - Recruiting
Phase
2
Condition
Warts
Treatment
Candida antigen vaccine
Bivalent HPV vaccine
Clinical Study ID
NCT05291845
C.ag-vs-B.HPV.V
Ages > 9 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- patients with multiple, recalcitrant, or non-recalcitrant common warts of differentsites, sizes, duration, and with or without distant lesions will be enrolled in thestudy
Exclusion
Exclusion Criteria:
- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Study Design
Total Participants: 162
Treatment Group(s): 2
Primary Treatment: Candida antigen vaccine
Phase: 2
Study Start date:
April 03, 2022
Estimated Completion Date:
December 06, 2025
Study Description
Connect with a study center
Reham Essam
Zagazig, Al Sharqia 2543
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.